Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christos Chouaid

Showing results (51-60 of 209) with videos related to

Pageof 21
Sort By:
Proceedings of the American Thoracic Society|August 22, 2006
Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary diseaseSaadia Eddahibi, Ari Chaouat, Li Tu, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 20, 2024
Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic DriversLaura Bender Somme, Christos Chouaid, Fabien Moinard-Butot, et al.
Oncology|October 25, 2017
Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)Jaafar Bennouna, Lionel Falchero, Roland Schott, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2023
Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling studyIngrid Plessala, Hélène Cawston, Justine Cortes, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 21, 2012
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerAlain Vergnenègre, Joshua A Ray, Christos Chouaid, et al.
Lung Cancer (Amsterdam, Netherlands)|December 25, 2025
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA studyRomain Supiot, Alexandre Gherardi, Léopoldine du Manoir de Juaye, et al.
BMJ Supportive & Palliative Care|October 28, 2021
Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experimentFlorian Scotte, Hélène Simon, Philippe Laplaige, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 2, 2017
A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in FranceKaisa Taipale, Katherine B Winfree, Mark Boye, et al.
Respiratory Medicine|December 27, 2011
Chronic bronchitis in the general population: influence of age, gender and socio-economic conditionsAlexis Ferré, Claire Fuhrman, Mahmoud Zureik, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 11, 2017
Cost analysis of adverse events associated with non-small cell lung cancer management in FranceChristos Chouaid, Delphine Loirat, Emilie Clay, et al.
Pageof 21

Showing results (51-60 of 209) with videos related to

Sort By:
Pageof 21
Proceedings of the American Thoracic Society|August 22, 2006
Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary diseaseSaadia Eddahibi, Ari Chaouat, Li Tu, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|May 20, 2024
Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-Small Cell Lung Carcinoma with or without Alterations in Oncogenic DriversLaura Bender Somme, Christos Chouaid, Fabien Moinard-Butot, et al.
Oncology|October 25, 2017
Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE)Jaafar Bennouna, Lionel Falchero, Roland Schott, et al.
Lung Cancer (Amsterdam, Netherlands)|August 10, 2023
Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling studyIngrid Plessala, Hélène Cawston, Justine Cortes, et al.
Clinicoeconomics and Outcomes Research : CEOR|February 21, 2012
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancerAlain Vergnenègre, Joshua A Ray, Christos Chouaid, et al.
Lung Cancer (Amsterdam, Netherlands)|December 25, 2025
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA studyRomain Supiot, Alexandre Gherardi, Léopoldine du Manoir de Juaye, et al.
BMJ Supportive & Palliative Care|October 28, 2021
Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experimentFlorian Scotte, Hélène Simon, Philippe Laplaige, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 2, 2017
A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in FranceKaisa Taipale, Katherine B Winfree, Mark Boye, et al.
Respiratory Medicine|December 27, 2011
Chronic bronchitis in the general population: influence of age, gender and socio-economic conditionsAlexis Ferré, Claire Fuhrman, Mahmoud Zureik, et al.
Clinicoeconomics and Outcomes Research : CEOR|August 11, 2017
Cost analysis of adverse events associated with non-small cell lung cancer management in FranceChristos Chouaid, Delphine Loirat, Emilie Clay, et al.
Pageof 21